ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Kite and Appia Bio to develop allogeneic cell therapies for blood cancer
August 09, 2021Gilead unit Kite and Appia Bio have signed a partnership and licence agreement to research and develop off-the-shelf allogeneic cell treatments from hematopoietic stem cells (HSCs) for haematological cancers. -
Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer
August 06, 2021Kite, a Gilead Company, and Appia Bio, Inc. announced a collaboration and license agreement to research and develop HSC-derived cell therapies directed toward hematological malignancies. -
Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities
June 15, 2021Cellectis S.A., a clinical-stage biotechnological company employing its core proprietary technologies to develop products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor (CAR) T-cells in the field of immuno-oncology
Pharma Sources Insight January 2025
